WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

Drashti Shah*, Manya Trivedi, Vishruti Shah, Keyur Mistry, Vanshi Kabrawala, Dhanvi Bhatt

ABSTRACT

Significant advancements in the treatment of inflammatory bowel disease (IBD) over the past decade have focused on achieving sustained clinical remission and minimizing the side effects of conventional therapies. Traditionally, IBD management relies on aminosalicylates, corticosteroids, and antimicrobials. For patients who do not respond to these therapies, more targeted treatments such as calcineurin inhibitors (e.g., cyclosporine) and biologic agents, including TNF-α inhibitors (e.g., infliximab, adalimumab) and anti-cell adhesion molecules (e.g., vedolizumab, natalizumab), are utilized. These therapies specifically target pro-inflammatory cytokines such as TNF-α, IL-2, and integrin α4β7. Recent developments in IBD treatment have introduced novel biologics, small-molecule drugs, and biosimilars, which provide new therapeutic options with improved efficacy and safety profiles. Additionally, there is growing interest in the role of gut microbiome modulation through probiotics, prebiotics, and dietary interventions in the management of IBD. Stem cell transplantation and fecal microbiota transplantation are also being explored as promising therapeutic strategies for refractory cases. These advancements represent a significant shift towards more personalized and effective treatment approaches, offering hope for better outcomes and improved quality of life for patients with IBD. This review provides a comprehensive overview of these emerging therapies and their potential to revolutionize IBD management.

[Full Text Article] [Download Certificate]